Clinical trial
Phase 1 Open-Label Pharmacokinetic, Safety and Tolerability Study of a Single Subcutaneous Dose of Glymera (PB1023) Injection in Subjects With Normal Renal Function and Subjects With Impaired Renal Function
NCT01478399 is registered in ClinicalTrials.gov with PhaseBio Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1 Open-Label Pharmacokinetic, Safety and Tolerability Study of a Single Subcutaneous Dose of Glymera (PB1023) Injection in Subjects With Normal Renal Function and Subjects With Impaired Renal Function
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2011
- Completion date
- October 31, 2012
- Enrollment
- 16 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.